PubRank

A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection

Clinical Trial ID NCT01829971

PubWeight™ 88.60‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01829971

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013 3.33
2 MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer. Theranostics 2015 1.62
3 miR-34: from bench to bedside. Oncotarget 2014 1.59
4 Progress in microRNA delivery. J Control Release 2013 1.58
5 The biological functions of miRNAs: lessons from in vivo studies. Trends Cell Biol 2014 1.47
6 MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA Cancer J Clin 2014 1.40
7 MicroRNA-34a: a potential therapeutic target in human cancer. Cell Death Dis 2014 1.32
8 A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene 2014 1.29
9 MicroRNA Processing and Human Cancer. J Clin Med 2015 1.23
10 MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. Cell Death Differ 2014 1.17
11 MiRNA-based therapeutic intervention of cancer. J Hematol Oncol 2015 1.14
12 MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia 2014 1.08
13 Clinical applications of microRNAs. F1000Res 2013 1.07
14 Current Therapeutic Advances Targeting EGFR and EGFRvIII in Glioblastoma. Front Oncol 2015 1.05
15 Combinatorial Action of MicroRNAs let-7 and miR-34 Effectively Synergizes with Erlotinib to Suppress Non-small Cell Lung Cancer Cell Proliferation. Cell Cycle 2015 1.05
16 MicroRNAs as Molecular Targets for Cancer Therapy: On the Modulation of MicroRNA Expression. Pharmaceuticals (Basel) 2013 1.04
17 The emerging role of miRNAs in inflammatory bowel disease: a review. Therap Adv Gastroenterol 2015 1.03
18 Role of microRNAs in hepatocellular carcinoma: a clinical perspective. Onco Targets Ther 2013 1.02
19 Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov 2015 1.02
20 Targeting microRNAs in pancreatic cancer: microplayers in the big game. Cancer Res 2013 1.01
21 Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev 2014 1.00
22 MicroRNAs in Cancer: A Historical Perspective on the Path from Discovery to Therapy. Cancers (Basel) 2015 0.99
23 MicroRNAs and Potential Targets in Osteosarcoma: Review. Front Pediatr 2015 0.98
24 MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets? Oncotarget 2015 0.98
25 Therapeutic Opportunities for Targeting microRNAs in Cancer. Mol Cell Ther 2014 0.94
26 MicroRNA regulation and therapeutic targeting of survivin in cancer. Am J Cancer Res 2014 0.93
27 MicroRNAs: promising new antiangiogenic targets in cancer. Biomed Res Int 2014 0.91
28 MicroRNAs as therapeutic targets in human cancers. Wiley Interdiscip Rev RNA 2014 0.91
29 Signaling by exosomal microRNAs in cancer. J Exp Clin Cancer Res 2015 0.90
30 Vascular remodeling process in pulmonary arterial hypertension, with focus on miR-204 and miR-126 (2013 Grover Conference series). Pulm Circ 2014 0.90
31 miRNA therapeutics in cardiovascular diseases: promises and problems. Front Genet 2015 0.89
32 MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics. Cancer Med 2016 0.89
33 Noncoding RNAs: key molecules in understanding and treating pain. Trends Mol Med 2014 0.89
34 Functional proteomics identifies miRNAs to target a p27/Myc/phospho-Rb signature in breast and ovarian cancer. Oncogene 2015 0.88
35 Drug development: try and try again. Nature 2014 0.88
36 MicroRNAs: promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. World J Gastroenterol 2014 0.87
37 Can nanomedicines kill cancer stem cells? Adv Drug Deliv Rev 2013 0.86
38 Regulation of cancer metastasis by microRNAs. J Biomed Sci 2015 0.86
39 Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma. World J Hepatol 2015 0.86
40 Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. Mol Cell Ther 2013 0.86
41 Novel Evidence for Curcumin and Boswellic Acid-Induced Chemoprevention through Regulation of miR-34a and miR-27a in Colorectal Cancer. Cancer Prev Res (Phila) 2015 0.85
42 MicroRNA-206: a promising theranostic marker. Theranostics 2014 0.85
43 Non-Coding RNAs in Primary Liver Cancer. Front Med (Lausanne) 2015 0.85
44 The potential of microRNAs in personalized medicine against cancers. Biomed Res Int 2014 0.84
45 MicroRNA and MET in lung cancer. Ann Transl Med 2015 0.84
46 Targeting Intracellular Cholesterol is a Novel Therapeutic Strategy for Cancer Treatment. J Cancer Sci Ther 2014 0.84
47 MicroRNA-218 enhances the radiosensitivity of human cervical cancer via promoting radiation induced apoptosis. Int J Med Sci 2014 0.84
48 MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma. World J Gastroenterol 2016 0.84
49 MicroRNAs in cancer therapeutics: "from the bench to the bedside". Expert Opin Biol Ther 2015 0.84
50 Emerging role of microRNA-21 in cancer. Biomed Rep 2016 0.84
51 miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma. Physiol Genomics 2013 0.83
52 The tumor-suppressive and potential therapeutic functions of miR-34a in epithelial carcinomas. Expert Opin Ther Targets 2015 0.82
53 MicroRNAs in cardiovascular ageing. J Physiol 2015 0.82
54 microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB. Oncotarget 2016 0.82
55 microRNA-34a as a Therapeutic Agent against Human Cancer. J Clin Med 2015 0.81
56 MicroRNA and Heart Failure. Int J Mol Sci 2016 0.81
57 RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Oncotarget 2016 0.81
58 MicroRNAs in multiple myeloma and related bone disease. Ann Transl Med 2015 0.81
59 MicroRNA aberrations: An emerging field for gallbladder cancer management. World J Gastroenterol 2016 0.81
60 MicroRNA Therapeutics: the Next Magic Bullet? Mini Rev Med Chem 2015 0.80
61 HPV E6/p53 mediated down-regulation of miR-34a inhibits Warburg effect through targeting LDHA in cervical cancer. Am J Cancer Res 2016 0.79
62 Emerging Roles for MicroRNAs in Perioperative Medicine. Anesthesiology 2016 0.79
63 Noncoding RNAs: emerging players in muscular dystrophies. Biomed Res Int 2014 0.79
64 Novel RNA markers in prostate cancer: functional considerations and clinical translation. Biomed Res Int 2014 0.79
65 miRNA interventions serve as 'magic bullets' in the reversal of glioblastoma hallmarks. Oncotarget 2015 0.79
66 Nanoparticles as Drug Delivery Systems in Cancer Medicine: Emphasis on RNAi-Containing Nanoliposomes. Pharmaceuticals (Basel) 2013 0.78
67 Lipid nanoparticles for targeted siRNA delivery - going from bench to bedside. Int J Nanomedicine 2016 0.78
68 Dietary flaxseed modulates the miRNA profile in irradiated and non-irradiated murine lungs: a novel mechanism of tissue radioprotection by flaxseed. Cancer Biol Ther 2014 0.78
69 Epigenetics in liver disease: from biology to therapeutics. Gut 2016 0.78
70 MicroRNA-497 impairs the growth of chemoresistant neuroblastoma cells by targeting cell cycle, survival and vascular permeability genes. Oncotarget 2016 0.78
71 Activated Ras as a Therapeutic Target: Constraints on Directly Targeting Ras Isoforms and Wild-Type versus Mutated Proteins. ISRN Oncol 2013 0.78
72 Consumption of distinct dietary lipids during early pregnancy differentially modulates the expression of microRNAs in mothers and offspring. PLoS One 2015 0.77
73 MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. Tumour Biol 2016 0.77
74 Emerging role of hydrogen sulfide-microRNA crosstalk in cardiovascular diseases. Am J Physiol Heart Circ Physiol 2016 0.77
75 Hydroxyurea down-regulates BCL11A, KLF-1 and MYB through miRNA-mediated actions to induce γ-globin expression: implications for new therapeutic approaches of sickle cell disease. Clin Transl Med 2016 0.77
76 The biomolecular era for thoracic surgeons: the example of the ESTS Biology Club. J Thorac Dis 2014 0.77
77 Regulation of glucose metabolism in hepatocarcinogenesis by microRNAs. Gene Expr 2014 0.77
78 Lack of miR-133a Decreases Contractility of Diabetic Hearts: A Role for Novel Cross Talk Between Tyrosine Aminotransferase and Tyrosine Hydroxylase. Diabetes 2016 0.77
79 Getting miRNA Therapeutics into the Target Cells for Neurodegenerative Diseases: A Mini-Review. Front Mol Neurosci 2016 0.76
80 Decoding hepatocellular carcinoma: the promise of microRNAs. Hepatobiliary Surg Nutr 2014 0.76
81 Tackling Cancer Stem Cells via Inhibition of EMT Transcription Factors. Stem Cells Int 2016 0.76
82 A systematic in silico mining of the mechanistic implications and therapeutic potentials of estrogen receptor (ER)-α in breast cancer. PLoS One 2014 0.76
83 Aberrantly expressed miR-582-3p maintains lung cancer stem cell-like traits by activating Wnt/β-catenin signalling. Nat Commun 2015 0.76
84 Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism. Int J Mol Sci 2015 0.75
85 Export of microRNAs: A Bridge between Breast Carcinoma and Their Neighboring Cells. Front Oncol 2016 0.75
86 Identification of miR-34a-target interactions by a combined network based and experimental approach. Oncotarget 2016 0.75
87 Editorial: Molecular Function and Regulation of Non-coding RNAs in Multifactorial Diseases. Front Genet 2016 0.75
88 Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism. J Lipid Res 2015 0.75
89 Translational aspects in targeting the stromal tumour microenvironment: from bench to bedside. New Horiz Transl Med 2016 0.75
90 MicroRNAs as Therapeutic Targets in Colitis and Colitis-Associated Cancer: Tiny Players With a Giant Impact. Gastroenterology 2015 0.75
91 HDL and microRNA therapeutics in cardiovascular disease. Pharmacol Ther 2016 0.75
92 miR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer. Sci Rep 2016 0.75
93 MicroRNAs in the pathobiology of sarcomas. Lab Invest 2015 0.75
94 MicroRNA-Based Therapy in Animal Models of Selected Gastrointestinal Cancers. Front Pharmacol 2016 0.75
95 ApoptomiRs of Breast Cancer: Basics to Clinics. Front Genet 2016 0.75
96 MicroRNAs-from metastasis prediction to metastasis prevention? Mol Cell Oncol 2015 0.75
97 The role of microRNAs in bone metastasis. J Bone Oncol 2016 0.75
98 A novel p70 S6 kinase-microRNA biogenesis axis mediates multicellular spheroid formation in ovarian cancer progression. Oncotarget 2016 0.75
99 Current understanding of the functional roles of aberrantly expressed microRNAs in esophageal cancer. World J Gastroenterol 2016 0.75
Next 100